



JOINT MEETING

10TH BIC
INTERNATIONAL
CONFERENCE



inhibitOrs III
3rd INTERNATIONAL CONFERENCE
ON INHIBITORS IN HEMOPHILIA

HEMOPHILIAS - VWD and VWF - GENE THERAPY - TTP - HUS

▶ GENOA ITALY 6-8 SEPTEMBER 2019 ◀

Conference Venue: Palazzo Ducale
Piazza Giacomo Matteotti, 9 - Genoa

ORGANIZED BY



UNIVERSITÀ DEGLI STUDI DI MILANO



Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico



Sistema Socio Sanitario

Regione Lombardia



CENTRO EMOFILIA E TROMBOSI
ANGELO BIANCHI BONOMI

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

SCIENTIFIC COMMITTEE

| P.M. MANNUCCI, Italy | F. PEYVANDI, Italy

| N. CIAVARELLA, Italy | A.B. FEDERICI, Italy | D. LILICRAP, Canada | S. LACROIX-DESMAZES, France | P.J. LENTING, France | J. VOORBERG, The Netherlands

Replacement therapies in hemophilia A and B -
Efficacy of extended half-life products

08:30 **Real life data: real benefits. What have we achieved?**

Pratima Chowdari (UK)

09:00 **How to optimize the use of extended half-life
products (PK analysis)**

Alfonso Iorio (Canada)

Safety of replacement therapies (standard and
novel) (part I)

09:30 **Which bleeding phenotype can we expect in severe
hemophilia A previously untreated patients treated
with non replacement therapies?**

Karin Fijn van Draat (The Netherlands)

10:00 **How safety of novel anti-hemophilic drugs should be
approached. Known and unknown adverse effects**

Flora Peyvandi (Italy)

10:30 **Are Fc – FVIII products less immunogenic? New
clinical data?**

Christoph Königs (Germany)

Safety of replacement therapies (standard and
novel) (part II)

11:30 **Long-term side-effects of pegylated products: facts
or fancies?**

Silvio Garattini (Italy)

12:00 **European pharmacovigilance of new products (with
special emphasis on pegylated products)**

Anneliese Hilger (EMA, Germany)

12:30 **Immunogenicity of subcutaneous and intravenous
drugs**

David Lillicrap (Canada)

13:00 **Bayer Lunch Satellite Symposium**

TBA

14:00 **Takeda Satellite Symposium**

TBA

15:00 **Kedrion Satellite Lecture**

TBA

16:00 **Choice of assays for novel anti-hemophilic therapies**

Armando Tripodi (Italy)

The role of von Willebrand factor in factor VIII
immunogenicity

16:30 **FVIII peptide presentation to the immune system;
modulation by von Willebrand factor**

Jan Voorberg (The Netherlands)

17:00 **High von Willebrand factor affinity FVIII and
immunogenicity**

Peter Lenting (France)

17:30 **Walking Poster Session**

Non-replacement therapies in the hemophilias: Update

- 09:00 **Fitusiran**
Steve Pipe (USA)
- 09:30 **APC Serpin**
James Huntington (UK)
- 10:00 **Anti-TFPI**
Alan Mast (USA)
- 10:30 **Thrombotic microangiopathy associated with emicizumab: views from an insider**
Paul Coppo (France)

Novel drugs

- 11:30 **Caplacizumab: results of phase II/phase III studies**
Marie A. Scully (UK)

- 12:00 **Novo Nordisk Satellite Lecture**
TBA

- 12:30 **Roche Satellite Lecture**
TBA

- 13:00 **Octapharma Lunch Satellite Symposium**
TBA

Gene Therapy

- 14:00 **New strategies for a better and safer gene transfer: less immunogenic**
Luigi Naldini (Italy)
- 15:00 **Liver toxicity in gene therapy**
Amit Nathwani (UK)

- 15:30 **Oral Communications**

Immunotolerance induction in hemophilia (Part I)

- 16:00 **How to maintain tolerance in hemophilia A**
Sébastien Lacroix-Desmazes (France)
- 16:30 **How to induce Treg responses in experimental hemophilia A**
Naro Biswas (USA)
- 17:00 **Is it important to induce immune tolerance in the era of non-replacement therapies?**
Elena Santagostino (Italy)
- 17:30 **Specific Treg therapy for hemophilia inhibitors: CARs versus BARs?**
David Scott (USA)

- 18:00 **Walking Poster Session**

Von Willebrand factor and ADAMTS13 in hemostasis and thrombosis

- 09:00 **Von Willebrand factor self-association role in hemostasis and thrombosis**
José Lopez (USA)
- 09:30 **Interactions of von Willebrand factor/ADAMTS13**
Jim Crawley (UK)
- 10:00 **Modulation of ADAMTS13 conformation (open/close) in TTP**
Karen Vanhoorelbeke (Belgium)
- 10:30 **Impact of cohort studies on therapeutic approaches for von Willebrand disease**
Jeroen Eikenboom (The Netherlands)
- 11:30 **Update on 3WINTERS**
Augusto B. Federici (Italy)
- 12:00 **Acquired von Willebrand disease**
Giancarlo Castaman (Italy)
- 12:30 **Role of von Willebrand factor in the vessel wall: interplay with vascular smooth muscle cells**
Cécile Denis (France)

14:00 | Oral Communications

Other clinical challenges of hemophilia

- 15:00 **Thrombosis in hemophilia: results from EUHASS Registry, including thrombotic microangiopathies**
Mike Makris (UK)
- 15:30 **Ageing with hemophilia**
Pier Mannuccio Mannucci (Italy)
- 16:00 **Eradication of HCV in Europe**
Massimo Colombo (Italy)

Immunotolerance induction in hemophilia (Part II)

- 17:00 **Gene-therapy-mediated tolerance induction**
Valter R. Arruda (USA)
- 17:30 **A working group on new concepts for ITI**
Kate Pratt (USA)